Philip Morris International (PM) vs Regencell Bioscience (RGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Philip Morris International (PM) has outperformed Regencell Bioscience (RGC) over the past year, gaining 29.1% versus a loss of 60.7%. Over five years, RGC leads with a +1455.6% price change compared with +103.8% for PM. Philip Morris International is the larger company by market cap ($313.58 billion vs $3.64 billion), about 86.0 times the size.
Philip Morris International pays a dividend yielding 2.92%, while Regencell Bioscience does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PM | RGC |
|---|---|---|
| Share price | $201.19 | $7.35 |
| Market cap | $313.58B | $3.64B |
| 1-day change | +0.34% | -3.67% |
| YTD return | +25.00% | -63.67% |
| 1-year return | +29.13% | -60.67% |
| 5-year return | +103.82% | +1455.56% |
| P/E ratio (TTM) | 28.91 | — |
| Forward P/E | 21.91 | — |
| EPS (TTM) | $6.96 | $-0.02 |
| Dividend yield | 2.92% | 0.00% |
| Annual dividend | $5.88 | $0.00 |
| Revenue (latest FY) | $40.65B | — |
| Revenue growth (YoY) | +7.31% | — |
| Net income (latest FY) | $11.35B | $-11.70M |
| Gross margin | 67.12% | — |
| Operating margin | 36.64% | — |
| Net margin | 27.92% | — |
| 52-week high | $207.76 | $69.00 |
| 52-week low | $142.11 | $4.51 |
| Distance from 52-week high | -3.16% | -89.35% |
| Analyst consensus | none | — |
| Avg. price target upside | +3.45% | — |
| Average volume | 4.66M | 199.19K |
| Shares outstanding | 1.56B | 495.88M |
| Employees | 84,900 | 10 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Philip Morris International is about 86.0 times larger than Regencell Bioscience by market value ($313.58B vs $3.64B).
- PM has outperformed RGC by 89.8 percentage points over the past year.
- Philip Morris International offers a meaningfully higher dividend yield (2.92% vs 0.00%).
About Philip Morris International
PM stock →Philip Morris International Inc. operates as a tobacco company.
Health Care · Medicinal Chemicals and Botanical Products · 84,900 employees
About Regencell Bioscience
RGC stock →Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 10 employees
PM vs RGC FAQ
Which is bigger, Philip Morris International or Regencell Bioscience?
Philip Morris International (PM) is larger, with a market capitalization of $313.58B compared with $3.64B for Regencell Bioscience (RGC).
Which stock has performed better over the past year, PM or RGC?
PM returned +29.13% over the past 12 months, compared with -60.67% for RGC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Philip Morris International or Regencell Bioscience?
Philip Morris International pays a dividend yielding 2.92%, while Regencell Bioscience does not currently pay a regular dividend.
Are Philip Morris International and Regencell Bioscience in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.